Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS will increase its volume of quality research
2009-11-25

 
From the left are, seated: Prof. Alice Pell, Vice-Provost: International Relations at Cornell University in the USA and Prof. Jonathan Jansen, Rector and Vice-Chancellor of the UFS; standing: Prof. Ezekiel Moraka, Vice-Rector: External Relations at the UFS, and Prof. David Wolfe from Cornell University during the signing of a memorandum of agreement between the two institutions.
Photo: Stephen Collett

The University of the Free State (UFS) is taking its research serious and is therefore going to increase its volume of quality research. This includes the production of quality scholarly books in the humanities and social sciences.

This was said by Prof. Jonathan Jansen, Rector and Vice-Chancellor, at the launch of the Strategic Academic Cluster initiative of the University on the Main Campus in Bloemfontein last night.

“We are going to produce the kind of research that is associated with scholarships. New models of training, new standards of performance and the introduction of an accelerated Vice-Chancellor’s Prestige Scholars’ Programme are among the initiatives that will be introduced. These are all aimed at boosting our university’s research performance,” said Prof. Jansen.

Another strategy to boost research performance at the UFS is the search for 25 leading professors to be appointed across the disciplines, but especially in the social sciences, education and the humanities. These positions have already been advertised and will be phased in with the goal of achieving equity and excellence in the academic and research profile of the UFS. “We’ve had an overwhelming response to the advertisements from local academics as well as those abroad,” said Prof. Jansen.

Each of the six Cluster Directors gave a short presentation of its aim and focus areas during last night’s dinner. These Clusters will in future direct the University’s research endeavours. It represents a move from a fragmented to a more focused approach to research development at the UFS.

The UFS also signed a memorandum of agreement with Cornell University (USA) last night. The guest speaker, Prof. Alice Pell, Vice-Provost: International Relations at Cornell University and member of the UFS’s International Advisory Board, said that, just as the cluster research teams need representatives from different disciplines, universities need diverse partners to recognise their potential fully. Collaborating with partners with ‘fresh eyes’ that have different cultural perspectives, access to different technologies and partners with different priorities can have important implications in the research and education provided by the UFS and Cornell,” she said.

“The interdisciplinary approach adopted by the UFS in developing the Strategic Academic Clusters seems likely to provide students with the intellectual frameworks and research tools that they need to address the problems in society,” she said.

“The most important issues facing the USA and South Africa are similar, namely how to effect the social transformation that will provide equal opportunities to all of our citizens. South Africa, Brazil, India and the USA share strong commitments to democracy, to overcoming our dark histories of religious and racial discrimination and to sustainable economic development without adverse impacts on our planet. We at Cornell are excited about the opportunity to work with the UFS on all of the clusters, but we are particularly looking forward to learning more about social transformation,” said Prof. Pell.

Media release
Issued by: Lacea Loader
Deputy Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
24 November 2009

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept